MBIO - ムスタング・バイオ (Mustang Bio Inc.) ムスタング・バイオ

 MBIOのチャート


 MBIOの企業情報

symbol MBIO
会社名 Mustang Bio Inc (ムスタング・バイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Mustang Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology which uses the patient’s own T cells to engage and destroy specific tumors. The Company through its agreement with City of Hope National Medical Center is using three novel CAR T therapies in the development of cancer treatments including human epidermal growth factor receptor 2 CAR T technology CS1-specific CAR T technology and prostate stem cell antigen CAR T technology.   ムスタング・バイオは米国のバイオ医薬品企業。臨床段階で、免疫療法によるがん治療法の開発・商業化に従事する。患者自身の免疫システムの効果を利用し、がん細胞を排除する治療法に焦点を当てる。同社は研究開発のためライセンス供与などでテクノロジ―の所有権を取得し、最終的にはテクノロジ―を市場に投入する方向。本社所在地はニューヨーク。   Mustang Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells.
本社所在地 2 Gansevoort Street 9th Floor New York NY 10014 USA
代表者氏名
代表者役職名
電話番号 +1 781-652-4507
設立年月日 42064
市場名 NASDAQ National Market System
ipoyear ―年
従業員数
url www.mustangbio.com
nasdaq_url https://www.nasdaq.com/symbol/mbio
adr_tso
EBITDA EBITDA(百万ドル) -34.35600
終値(lastsale) 5.25
時価総額(marketcap) 143132608.5
時価総額 時価総額(百万ドル) 126.22930
売上高 売上高(百万ドル) 0.05000
企業価値(EV) 企業価値(EV)(百万ドル) 79.48530
当期純利益 当期純利益(百万ドル) -33.91500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mustang Bio Inc revenues increased from $0K to $50K. Net loss increased 30% to $11.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.2M to $7.8M (expense) General and administrative increase of 3% to $3.8M (expense).

 MBIOのテクニカル分析


 MBIOのニュース

   GEVO, TRQ among premarket gainers  2019-05-16
Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ムスタング・バイオ MBIO Mustang Bio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)